AstraZeneca is unveiling a wealth of data at the European Society for Medical Oncology (ESMO) Congress from October 20 to 24, 2023, to further...
Assessing the Burden of Adult-Onset Still’s Disease on Patients and Healthcare Systems
Adult-onset Still's disease (AOSD) is found to pose an uncertain burden on patients and healthcare systems. In effort to estimate this burden, a systematic...
The Excess Health Burden of Drug-Resistant Bloodstream Infections in Europe
Antimicrobial resistance is a global threat that needs novel intervention strategies. The development of such strategies requires a determination of priority pathogens and settings....
GlaxoSmithKline Enters Exclusive Agreement with Zhifei to Boost Shingrix Availability in China
Global pharmaceutical giant GSK (GlaxoSmithKline) has announced a significant partnership with Chongqing Zhifei Biological Products, Ltd. (Zhifei), China's largest vaccine company by revenue. Under...
Sanofi has presented new data at the 28th Annual Congress of the World Muscle Society (WMS), highlighting the continued efficacy of Nexviazyme® (avalglucosidase alfa)...
Pfizer will share data from its infectious disease research at IDWeek 2023 in Boston, happening from October 11 to 15, 2023. This data, consisting...
Novavax Receives FDA Approval for Updated COVID-19 Vaccine Targeting XBB.1.5 Variant
The US Food and Drug Administration (FDA) has granted approval for Novavax to release an updated version of its COVID-19 vaccine specifically designed to...
a Successful Case Study Crafting Evidence Based Value Messages for Market Dominance
Navigating the complex landscape of market access is no small feat, especially when faced with stiff competition and limited resources. The MTRC (Market Access...
Imperial College Researchers Unearth Complex NHS Data Flow for Enhanced Transparency and Efficiency
For the first time, researchers from the Institute of Global Health Innovation at Imperial College London have comprehensively mapped and evaluated all electronic data...
Krystal Biotech submitted an application in August seeking approval for the initiation of a Phase I clinical trial of KB408. After a 30-day review...
